The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...

compared with patients who stayed on full-dose TNF inhibitors. Medscape Medical News, November 08, 2021 ACR 2021 Risankizumab Outperforms Placebo at 6 Months for Psoriatic Arthritis At the 24-week ...

In terms of competition, there are currently only two other IL-23 inhibitors approved in the US besides Tremfya – Eli Lilly’s Omvoh (mirikizumab) and AbbVie’s Skyrizi (risankizumab).

Generalized pustular psoriasis (GPP) can range in severity and may be life threatening for some people. Treatment typically includes a variety of topical, oral, and injectable medications. General ...

TNF inhibitors used in these patients included ... In the IL-23 inhibitor class were guselkumab (Tremfya), tildrakizumab (Ilumya), and risankizumab (Skyrizi), as well as the dual IL-12/23 ...

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to ...

Sorting Out the Many Mimickers of Psoriasis 'It has an earlier age of onset, usually in infancy, and can occur with the atopic triad that presents with asthma and seasonal allergies as well.

Dose reduction (DR) of first-generation biologics for plaque psoriasis (TNF-alpha inhibitors (i) and interleukin (IL)-12/23i) has been described in a previous scoping review. The literature on the DR ...

Figure 2 Studies of concordance for AS in UK twins recruited through the National Ankylosing Spondylitis Society. The clear difference on concordance rates between MZ twins and DZ twins is highly ...